Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCI/FDA collaboration

Executive Summary

FDA and National Cancer Institute unveil "inter-agency agreement" to accelerate cancer drug development in conjunction with American Society of Clinical Oncology meeting. Task force to increase collaboration between the two agencies will be co-chaired by FDA Assistant Commissioner for Planning Theresa Mullin, PhD, and NCI Deputy Director for Strategic Scientific Initiatives Anna Barker, PhD. FDA cited the collaboration with NCI with aiding approval of Millennium's multiple myeloma treatmentVelcade (1"The Pink Sheet" May 19, 2003, p. 3)...

You may also be interested in...



Cancer Drug Development To See “Vast Improvements” In Speed – Thompson

HHS Secretary Thompson vows to make "vast improvements" in expediting oncology drug development using the FDA/National Cancer Institute Interagency Oncology Task Force

Electronic INDs For Cancer Trials Planned Under FDA/NCI Collaboration

Creating a mechanism for electronic IND applications will be the first project undertaken by a collaboration between FDA and the National Cancer Institute

USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities

The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.

UsernamePublicRestriction

Register

PS041903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel